Form 4: BioAge CMO Sells Shares Under 10b5-1 Plan

BioAge Labs' Chief Medical Officer, Paul D. Rubin, exercised options and sold 7,433 shares of common stock on January 2, 2026, under a pre-arranged 10b5-1 trading plan.

Summary

• Paul D. Rubin, Chief Medical Officer of BioAge Labs, Inc. (BIOA), engaged in transactions on January 2, 2026.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on November 5, 2024.
• Rubin exercised options to acquire 5,433 shares of common stock at an exercise price of $4.11 per share.
• Rubin also exercised options to acquire 2,000 shares of common stock at an exercise price of $6.57 per share.
• Immediately following these acquisitions, Rubin sold a total of 7,433 shares of common stock.
• The shares were sold at a weighted average price of $12.8468 per share, with individual sales ranging from $12.571 to $13.242.
• After these transactions, Rubin's direct beneficial ownership of common stock is 0 shares.
• Rubin still beneficially owns 16,303 stock options with an exercise price of $4.11 and 7,383 stock options with an exercise price of $6.57.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction under a 10b5-1 plan, which is a common practice. While an insider sale can sometimes be viewed negatively, the pre-planned nature and the fact that it's an option exercise and sell-to-cover/liquidity event makes it less impactful than an unannounced, large-scale open market sale.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and not reactive sale.
• The sale price of $12.8468 per share is significantly higher than the exercise prices of $4.11 and $6.57, indicating a profitable transaction for the insider.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market, suggesting a lack of conviction in future price appreciation.
• The Chief Medical Officer's direct beneficial ownership of common stock is now 0 shares, though he retains significant option holdings.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook, as it is a report of insider transactions.

Industry Context

Insider transactions, particularly sales, are common across all industries as executives manage their personal portfolios and liquidity. The use of a 10b5-1 plan is a standard practice for insiders to sell shares in a pre-scheduled manner, mitigating concerns about trading on material non-public information. This specific transaction by BioAge Labs' CMO is a routine insider sale under such a plan.

Comparison to Industry Standards

• This Form 4 filing details a standard insider transaction involving option exercise and subsequent share sale under a Rule 10b5-1 plan.
• This practice is common among executives in publicly traded companies, including those in the biotechnology and pharmaceutical sectors like BioAge Labs.
• The use of a 10b5-1 plan aligns with best practices for corporate governance, providing a defense against insider trading allegations by pre-scheduling trades.
• There are no specific comparable companies, projects, or results mentioned in this transactional filing to assess against industry benchmarks beyond the procedural aspects of insider trading.

Stakeholder Impact

• Shareholders: May view the insider sale with mixed sentiment; some may see it as a normal liquidity event, while others might interpret it as a signal from management. The pre-planned nature mitigates negative impact.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 filing reports a routine insider transaction involving the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 trading plan. While an insider sale can sometimes be a bearish signal, the planned nature of this transaction, adopted months in advance, suggests it is for personal financial management rather than a reaction to new, negative material information. The Chief Medical Officer still retains significant unexercised options. Therefore, this specific filing alone does not provide sufficient new information to warrant a change in investment recommendation; a 'hold' stance is appropriate, pending further fundamental analysis of the company's operations and prospects.

Keywords

BioAge Labs, BIOA, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Paul D. Rubin, Chief Medical Officer, 10b5-1 Plan, Beneficial Ownership